To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.
Study Type
OBSERVATIONAL
Enrollment
3,338
Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
Number of Participants With Treatment Related Adverse Events.
Adverse events mean all unfavorable events that occur in participants after administration of Selara, irrespective of causal relationship to Selara (including clinically problematic abnormal changes in laboratory test values). Treatment Related Adverse Events were evaluated in company with the causal relationship to Selara.
Time frame: 12 weeks
Number of Participants With Serious Treatment Related Adverse Events.
Serious treatment related adverse events mean those that may lead to death, life-threatening, hospitalization or prolonged hospitalization, a permanent or remarkable disorder/dysfunction, congenital anomaly/congenital deficiency, or other medically significant events or disorder.
Time frame: 12 weeks
Change in Systolic Blood Pressure Over Time.
The primary analysis item was the mean systolic blood pressure at 4, 8, and 12 weeks of the observation period or at last evaluation date if Selara was terminated prematurely.
Time frame: 12 weeks
Change in Diastolic Blood Pressure Over Time.
The primary analysis item was the mean diastolic blood pressure at 4, 8, and 12 weeks of the observation period or at last evaluation date if Selara was terminated prematurely.
Time frame: 12 weeks
Number of Participants That Responded to Selara Treatment.
Number of participants among the efficacy analysis population that responded to Selara treatment.
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.